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CLINICAL SCIENCE
Temporal Association Between Incident Tuberculosis and
Poor Virological Outcomes in a South African Antiretroviral
Treatment Service
Ankur Gupta-Wright, Msc,* Robin Wood, DSc,† Linda-Gail Bekker, PhD,†
and Stephen D. Lawn, MD, FRCP*†
Introduction: The temporal relationship between incident tuber-
culosis (TB) and virological outcomes during antiretroviral therapy
(ART) is poorly deﬁned. This was studied in a cohort in Cape Town,
South Africa.
Methods: Data regarding TB diagnoses, ART regimens, and
4-monthly updated viral load (VL) and CD4 count measurements
were extracted from a prospectively maintained database. Rates of
virological breakthrough (VL . 1000 copies/mL) and failure (VL .
1000 copies/mL on serial measurements) following initial VL sup-
pression were calculated. Poisson models were used to calculate
incidence rate ratios (IRRs) and identify risk factors for these viro-
logical outcomes.
Results: Incident TB was diagnosed in 391 (28.5%) of 1370
patients during a median of 5.2 years follow-up. Five hundred
seventy-eight episodes of virological breakthrough and 231 episodes
of virological failure occurred, giving rates of 10.0 episodes per 100
person-years and 4.0 episodes per 100 person-years, respectively. In
multivariate analyses adjusted for baseline and time-updated risk
factors, TB was an independent risk factor for adverse virological
outcomes. These associations were strongly time dependent; the
6-month period following diagnosis of incident TB was associated
with a substantially increased risk of virological breakthrough
(IRR: 2.3, 95% conﬁdence interval: 1.7 to 3.2) and failure (IRR:
2.6, 95% conﬁdence interval: 1.6 to 4.3) compared with time
without a TB diagnosis. Person-time preceding TB diagnosis or
more than 6 months after a TB diagnosis was not associated with
poor virological outcomes.
Conclusions: Incident TB during ART was strongly associated
with poor virological outcomes during the 6-month period following
TB diagnosis. Although underlying mechanisms remain to be
deﬁned, patients with incident TB may beneﬁt from virological
monitoring and treatment adherence support.
Key Words: tuberculosis, HIV, viral load, virological failure, anti-
retroviral, Africa
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INTRODUCTION
HIV-associated tuberculosis (TB) remains a substantial
challenge to global health, especially in sub-Saharan Africa
where the majority of new cases and deaths occur.1 This burden
of disease is of particular importance to antiretroviral treatment
(ART) programs in the region as HIV-associated TB is con-
centrated in patients accessing these services.2–4 Signiﬁcant
progress has been made in strategies and policies regarding
screening, diagnosis, management, and prevention of HIV-
associated TB in ART programs.4–8 Nevertheless, the burden
of incident TB in patients receiving long-term ART remains
high, even in those with good immunological recovery, and this
may potentially have adverse effects on ART outcomes.9–11
Establishing and maintaining virological suppression
during ART is key to achieving favorable long-term clinical
outcomes and to reducing HIV transmission risk. Although
incident TB in patients receiving ART has been independently
associated with mortality, some evidence also suggests a link
between incident TB and viremia or virological failure.11–14
However, much of this evidence is from cross-sectional stud-
ies, the relationship is incompletely deﬁned, and, in particular,
the temporal relationship is unknown. It is mechanistically
plausible that virological failure, and subsequent immunologi-
cal failure, could result in increased risk of incident TB. Alter-
natively, the risk of virological failure might be increased
during concurrent ART and TB treatment because of impaired
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treatment adherence or pharmacokinetic drug interactions. The
aim of this study conducted in a community-based ART pro-
gram with high burden of TB in Cape Town, South Africa, was
to characterize the association between incident TB and poor
virological outcomes and to speciﬁcally characterize the tem-
poral relationship.
METHODS
Study Setting
This study was part of ongoing research at the ART
service in Gugulethu township, Cape Town, which has
previously been well described.3,15–17 Patients enrolled con-
secutively into the ART program from September 2002 were
eligible for the study. Blood CD4 cell counts and plasma viral
load (VL) levels were measured routinely pretreatment, every
4 months during ART, and when clinically indicated. VL
assays were measured using the Versant HIV-1 RNA 3.0
assay performed on a 340 bDNA analyzer (Bayer Diagnos-
tics, Tarrytown, NY) with a lower limit of detection of 50
RNA copies per milliliter.
First-line ART comprised the nonnucleoside reverse
transcriptase inhibitor efavirenz (EFV) or nevirapine (NVP)
with a nucleoside reverse transcriptase inhibitor backbone
(stavudine and lamivudine). The second-line regimen was
protease inhibitor (PI) based (lopinavir/ritonavir) with nucle-
oside reverse transcriptase inhibitor backbone (zidovudine
and didanosine). For those receiving NVP, a standard induc-
tion dose was used for all patients as per standard practice at
the time. The PI dose was doubled during rifampicin-based
TB treatment. A secure supply of medication was maintained
by the local health authority with no stockouts during the
study period, and all treatment was supplied free of charge.
Patients were allocated to community-based therapeutic
counselors for ongoing support. Patients did not receive
isoniazid preventive therapy as was practice at that time.
Virological Definitions
Virological suppression was deﬁned as at least 1 plasma
VL measurement , 50 copies per milliliter. Virological break-
through was deﬁned as a single plasma VL . 1000 copies per
milliliter having previously achieved virological suppression.
Two or more consecutive VL measurements . 1000 copies
per milliliter at least 4 weeks apart were deﬁned as virological
failure. Patients with a VL . 1000 copies per milliliter were
reviewed and received a targeted adherence intervention includ-
ing counselor home visits, as previously described.17 Although
a previous study reported similar proportions of patients with
VL measurements.400 and.1000 copies per milliliter during
ART,17 the threshold of 1000 copies per milliliter was chosen
as it is less likely to reﬂect random variation and more likely
to reﬂect signiﬁcant viral breakthrough.
TB Screening, Diagnosis, and Definitions
TB screening, diagnosis, and treatment have been pre-
viously described in this cohort.10 TB screening was conducted
at baseline using a multisymptom screening questionnaire sim-
ilar to the subsequently developed WHO-recommended screen6
to identify patients who required further investigation. All cases
of TB fulﬁlled WHO diagnostic criteria for resource-constrained
settings with high HIV prevalence.18 Any culture-negative TB
diagnoses were deﬁned by radiological abnormalities consistent
with active TB, strong histological, or clinical evidence of active
TB and a clinician’s decision to treat with a full course of
anti-TB chemotherapy. All microbiological specimens were
analyzed in accredited laboratories, and all positive cultures
were speciated by polymerase chain reaction. TB treatment
was rifampicin based and administered via a local network
of community clinics providing a directly observed treat-
ment short-course strategy.
“History of TB” was deﬁned as a diagnosis of TB with
completion of anti-TB treatment before enrollment for ART.
“Prevalent TB” was deﬁned as patients taking anti-TB treat-
ment at the time of starting ART. “Incident TB” was deﬁned as
a new clinical episode of TB diagnosed after initiation of ART
irrespective of date of symptom onset. Patients with multiple
diagnoses of incident TB had completed a full course of anti-
TB treatment with resolution of symptoms between episodes.
Data Collection and Ethics
Data were collected from patients enrolled consecutively
into the ART programme between September 2002 and May
2006 until censoring of observations on January 1, 2011.
Patients not initiating ART, nonnaive to ART at enrollment,
aged younger than 16 years, or not achieving virological
suppression were excluded. Information on TB events was
obtained from prospectively maintained structured clinical
records. Laboratory results were transferred on a monthly basis
to an electronic database and information on ART regimen was
attained from electronic pharmacy records. Outcomes were
assigned to all patients as follows: alive and receiving ART,
death from any cause, transfer to another ART service, or lost
to follow-up (LTFU). LTFU was deﬁned as patients on ART
who were over 12 weeks late for a scheduled clinic appoint-
ment, failed to return to the ART program, and could not be
located by active community-based follow-up.
All patients enrolling in this cohort study provided
written, informed consent for data collection for research
purposes, and this was approved by the Research Ethics
Committee of the University of Cape Town.
Data Analysis
Data were analyzed using Stata version 11.0 (College
Station, TX). Person-time was accrued from the date of starting
ART until death, transfer, LTFU, or data censorship. Chi-
squared tests were used for comparing proportions, t tests for
comparing means, and Wilcoxon rank-sum tests for comparing
medians. All statistical tests were 2 sided at a value of 0.05.
Person-time was divided into intervals predeﬁned by
the laboratory monitoring done at least 4 monthly. Each
interval was categorized into strata according to the CD4 cell
count and viral load at the start of the interval. If CD4 cell
count or viral load measurements were missing for 1 or more
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intervals, a mean of the values for the preceding and subsequent
intervals were used (1.6% intervals). Person-time accrued with
plasma VL . 1000 copies per milliliter was excluded from the
analysis. After virological failure, if participants subsequently
achieved suppression they began accruing person-time again
from repeat virological suppression until a further outcome
event or data censorship. Person-time was also stratiﬁed by
time related to incident TB diagnoses.
Poisson regression models were used to calculate
incidence rate ratios (IRRs) with 95% conﬁdence intervals
(CIs) for time-updated and baseline characteristics. Random
effects modeling was used to account for clustering of person-
time for individuals with more than 1 episode of virological
breakthrough or failure. Multivariate models were constructed
using Poisson regression and based on forward selection;
a priori risk factors (age and ART regimen) and variables
identiﬁed as being associated with virological breakthrough
or failure during the crude analysis were included. Likelihood
ratio tests were used to investigate interactions between
variables, statistical hypotheses, and linear trends.
RESULTS
Patient Enrollment and Follow-Up
During the study period, 2000 patients enrolled in the
ART program. A total of 630 patients were excluded from this
study because they were aged younger than 16 years (n = 161),
were nonnaive to ART (n = 85), did not start ART for a variety
of reasons (n = 210), or did not achieve virological suppression
(n = 174) (Fig. 1). The remaining 1370 patients were eligible
for inclusion in the study.
The mean age of the cohort was 34 years, and the
majority of the patients were women (71.1%). Overall,
patients had advanced immunodeﬁciency at enrollment with
a median baseline CD4 cell count of 102 cells per microliter
[interquartile range (IQR): 52–156 cells/mL]. Patients in
whom incident TB was diagnosed during ART were younger,
less likely to have WHO stage 1 or 2 disease, and more likely
to have WHO stage 4 disease (Table 1). They were also more
likely to have a history of TB and prevalent TB compared
with those who did not.
During a median follow-up of 5.2 years (IQR: 3.2–5.9
years) of ART, 71.9% of person-time was on an EFV-based
ART regimen, 18.7% on an NVP-based regimen, and 9.2%
on a PI-based regimen (second line). One hundred thirteen
(8.2%) patients died and 259 (18.9%) were lost to follow-up.
A total of 449 episodes of incident TB were diagnosed in 391
(28.5%) patients, with 338 patients having 1 diagnosis and 53
patients having 2 diagnoses. Diagnoses of incident TB were
microbiologically conﬁrmed in 73.5% cases.
Virological Breakthrough and Failure
During a total of 5790 person-years (PY) of follow-up,
578 episodes of virological breakthrough were detected. One
FIGURE 1. Patient enrollment and
outcomes during follow-up.
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episode was recorded in 339 (24.7%) patients, 102 (7.5%)
patients had multiple episodes, and 929 (67.8%) patients
maintained virological suppression throughout. Of the viro-
logical breakthrough episodes, 231 (40.0%) subsequently met
the criteria for virological failure. In total, 200 (14.6%)
patients experienced virological failure. Overall, rates of
virological breakthrough and virological failure were 10.0
episodes/100 PY and 4.0 episodes/100 PY, respectively.
Incident TB and Virological Outcomes
Higher rates of virological breakthrough occurred in the
period following a diagnosis of incident TB compared with
person-time without a diagnosis of incident TB [14.3
episodes/100 PY (95% CI: 12.2 to 16.7) versus 9.0 epi-
sodes/100 PY (95% CI: 8.2 to 9.9), respectively]. The
corresponding rates for virological failure showed a similar
association [5.5 episodes/100 PY (95% CI: 4.3 to 7.1) versus
3.6 episodes/100 PY (95% CI: 3.1 to 4.2), respectively). Of
patients with diagnoses of incident TB, 35% subsequently
had episodes of virological breakthrough, of which one third
developed within 6 months (median: 83 days, IQR: 50–170
days). Virological failure developed in 12% patients follow-
ing diagnoses of incident TB, with over half of these episodes
developing within 6 months of TB diagnosis (median: 102
days, IQR: 40–164 days).
Risk Factors for Poor Virological Outcomes
and Temporal Relationship With Incident TB
Rates of virological breakthrough and failure were
calculated for person-time accrued within a range of updated
CD4 cell strata (Fig. 2). The highest rates were associated
with person-time with counts of 0–100 cells per microliter
(46.8 episodes/100 PY; 95% CI: 37.2 to 58.9; 156 PY), and
the lowest rates were associated with person-time with counts
of .500 cells per microliter (3.2 episodes/100 PY; 95% CI:
2.4 to 4.1; 1802 PY). The relationship between rates of viro-
logical failure and updated CD4 cell counts showed a similar
pattern (Fig. 2).
In unadjusted analyses, time-updated CD4 cell counts
were the strongest risk factor for virological breakthrough
(Table 2). Other risk factors for increased rates of virological
breakthrough included younger age, increased duration of
ART, NVP- or PI-based ART, and diagnoses of incident
TB. Age, duration of ART, updated CD4 cell counts, ART
regimen, and incident TB were included in the multivariate
model (Table 2). There were no interactions between varia-
bles. Time-updated CD4 cell counts remained the strongest
risk factor for virological breakthrough, with the lowest
CD4 cell count stratum having over 30 times the risk of
virological breakthrough than the highest stratum (IRR:
33.7, 95% CI: 22.2 to 51.2, P , 0.001). Duration of ART
and age also remained strongly associated with virological
breakthrough (P , 0.001 for both). After adjustment for
other risk factors, NVP-based ART was independently asso-
ciated with increased risk of virological breakthrough (IRR:
1.35, 95% CI: 1.1 to 1.7) compared with EFV-based ART,
but no independent association was observed with PI-based
ART (Table 2).
In multivariate analysis, the risk of virological break-
through in the 6-month period following a diagnosis of TB
was associated with over twice the risk of virological
breakthrough compared with person-time without a TB
diagnosis (IRR: 2.3, 95% CI: 1.7 to 3.2, P , 0.001). The
6-month period before TB diagnosis or time more than 6
months after TB diagnosis were not associated with increased
risk of virological breakthrough after adjustment for other risk
factors (IRR: 0.8, 95% CI: 0.5 to 1.3, and IRR: 0.9 95% CI:
0.7 to 1.1, respectively) (Fig. 3).
In unadjusted and multivariate analyses (Table 2), risk
factors for virological failure were similar to those for viro-
logical breakthrough. Diagnoses of incident TB remained an
independent risk factor for virological failure, even after
TABLE 1. Patient Characteristics at Initiation of Antiretroviral Therapy
All Patients
(n = 1370)
No Diagnosis of Incident TB
During ART (n = 979)
Diagnosis of Incident TB
During ART (n = 391) P*
Mean age (yr) 34.0 34.3 33.2 0.011
Gender
Male 396 (28.9) 270 (27.6) 126 (32.2) 0.087
WHO stage
1 and 2 284 (20.7) 220 (22.5) 64 (16.4)
3 768 (56.1) 551 (56.3) 217 (55.5) 0.005
4 318 (23.2) 208 (21.3) 110 (28.1)
Baseline CD4 cell count (cells/mL)
Median (IQR) 102 (52–156) 104 (54–160) 97 (59–149) 0.141
Baseline viral load (log10 copies/mL)
Median (IQR) 4.85 (4.45–5.25) 4.84 (4.41–5.25) 4.88 (4.50–5.25) 0.493
History of TB† 640 (46.8) 422 (43.2) 218 (55.8) ,0.001
Prevalent TB‡ 395 (28.8) 304 (31.1) 91 (23.3) 0.004
Data are numbers (%) unless otherwise stated.
* Calculated using x2 tests for proportions, t tests for means, and Wilcoxon rank-sum tests for medians.
† Includes all TB episodes where anti-TB treatment was completed before ART enrollment.
‡ TB episodes where patients are taking anti-TB treatment at ART initiation.
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adjustment for other risk factors (P = 0.004). Risk of virolog-
ical failure was increased over 2.6 times during the 6-month
period following a diagnosis of incident TB compared with
person-time without a TB diagnosis (IRR: 2.6, 95% CI: 1.6
to 4.3). The 6-month period preceding incident TB diagnosis or
time more than 6 months after TB diagnosis were not associ-
ated with an increased risk virological failure after adjustment
for other risk factors (IRR: 1.3, 95% CI: 0.7 to 2.5, and IRR:
1.0 95% CI: 0.6 to 1.4, respectively) (Fig. 3). ART regimen
was not a risk factor for virological failure overall, but NVP-
based ART regimens were associated with an increased risk of
virological failure (IRR: 1.5, 95% CI: 1.0 to 2.2).
A sensitivity analysis similarly found increased adjusted
risks of virological breakthrough and failure (IRR: 2.3, 95%
CI: 1.6 to 3.3, P, 0.001, and IRR 3.1, 95% CI: 1.9 to 5.2, P =
0.002, respectively) in the 6 months after microbiologically
conﬁrmed diagnosis of incident TB but not in the periods either
preceding or more than 6 months after TB diagnosis.
Temporal Relationship With Prevalent TB
at Baseline
An exploratory analysis was also performed of the
association between prevalent TB and virological failure. As
previously, only person-time following initial virological sup-
pression was included and to provide adequate person-time for
analysis, a 12-month period was considered. In adjusted
analysis, the risks of virological breakthrough or failure
following prevalent TB were greater during the ﬁrst 12 months
of ART compared with .12 months after starting ART (IRR:
1.7, 95% CI: 1.0 to 2.8, P = 0.053 and IRR: 1.4, 95% CI: 0.9 to
2.0, P = 0.072, respectively).
DISCUSSION
Virological breakthrough and virological failure were
common events during ART in this South African cohort, and
the key ﬁnding of this study was that the rates of both were
substantially higher in the 6-month period after a diagnosis of
incident TB (but not in the periods either preceding or more
than 6 months after TB diagnosis). Over one third of patients
who developed incident TB during ART subsequently
developed virological breakthrough and 12% developed
virological failure. Incident TB was an independent risk
factor for both virological outcomes, having adjusted for
a wide range of baseline and time-updated variables. These
data highlight an important issue that has not previously been
clearly deﬁned and indicate the need, where possible, for
virological monitoring following diagnosis of incident TB,
adherence support, and other interventions that may be
required to address the underlying mechanisms.
Few studies have reported data on virological break-
through and failure rates during ART in sub-Saharan Africa.19
The high cumulative proportion of patients experiencing viro-
logical breakthrough and failure in this study may reﬂect the
long duration of follow-up, and rates are consistent with data
from other studies elsewhere in the world.20–23 Virological
breakthrough differs from virological failure in that the major-
ity of patients experiencing breakthrough will virologically
suppress following adherence interventions.17 The signiﬁ-
cance of virological breakthrough has yet to be clearly
deﬁned, and a better understanding and correlation with
clinical outcomes is needed. There is conﬂicting evidence
as to whether low-level viremia (commonly deﬁned as
50–400 copies/mL) during ART is associated with virological
failure.24–28 Blips of increasing magnitude (eg, .500
copies/mL), however, have been associated with virological
failure and resistance.29 Virological breakthrough in this
study was conservatively deﬁned as .1000 copies per milli-
liter and was thus unlikely to be because of stochastic varia-
tion and represented patients at increased risk of virological
failure, resistance, and poor clinical outcomes.
The data from this study did not support the hypoth-
esis that virological failure in this cohort results in the
FIGURE 2. Unadjusted association
between virological breakthrough
rates (95% CI), virological failure
rates (95% CI), and time-updated
CD4 cell counts.
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TABLE 2. Unadjusted and Multivariate Analyses of Risk Factors for Virological Breakthrough and Virological Failure During ART
Virological Breakthrough
Unadjusted Analysis Multivariate Analysis
IRR (95% CI) P IRR (95% CI) P
Age at enrollment* 0.97 (0.96 to 0.99) ,0.001 0.96 (0.95 to 0.97) ,0.001
Gender
Female 1
Male 0.93 (0.75 to 1.15) 0.521
WHO stage at enrollment
1 and 2 1
3 1.21 (0.95 to 1.55) 0.120
4 0.98 (0.73 to 1.32)
Baseline CD4 cell count (cells/mL)
$150 1
100–149 0.97 (0.73 to 1.29)
50–99 1.10 (0.83 to 1.44) 0.458
,50 1.19 (0.91 to 1.56)
Baseline viral load (log10 copies/mL)
,5 1
$5 1.17 (0.96 to 1.43) 0.122
Duration of ART (mo)
,24 1 1
24–36 1.38 (1.09 to 1.76) 2.68 (2.08 to 3.46)
36–48 1.50 (1.18 to 1.92) ,0.001 3.30 (2.53 to 4.32) ,0.001
48–60 1.60 (1.24 to 2.07) 4.01 (3.02 to 5.33)
.60 1.87 (1.43 to 2.44) 5.34 (3.93 to 7.26)
Updated CD4 cell count (cells/mL)†
.500 1 1
401–500 1.57 (1.07 to 2.31) 2.04 (1.38 to 3.02)
301–400 3.07 (2.22 to 4.25) 4.86 (3.48 to 6.79)
201–300 4.05 (2.95 to 5.54) ,0.001 8.18 (5.85 to 11.44) ,0.001
101–200 7.12 (5.22 to 9.72) 17.85 (12.57 to 25.33)
0–100 15.58 (10.83 to 22.41) 33.71 (22.18 to 51.24)
ART regimen†
Efavirenz based 1.00 1
Nevirapine based 1.27 (1.01 to 1.60) 1.34 (1.05 to 1.72)
PI based 1.68 (1.29 to 2.20) 0.002 1.08 (0.81 to 1.43) 0.091
Other 1.34 (0.14 to 12.70) 3.79 (0.43 to 33.22)
History of TB‡
No 1
Yes 0.99 (0.81 to 1.19) 0.884
Prevalent TB at baseline§
No 1
Yes 1.09 (0.88 to 1.35) 0.413
Incident TB†
No 1
Yes 1.73 (1.39 to 2.14) ,0.001
No incident TB 1 1
6-mo period before TB diagnosis 1.25 (0.77 to 2.03) 0.37 0.78 (0.47 to 1.31)
6-mo period after TB diagnosis 4.16 (3.06 to 5.64) ,0.001 2.32 (1.68 to 3.20) ,0.001
Time . 6 mo after TB diagnosis 1.33 (1.04 to 1.70) 0.024 0.89 (0.69 to 1.14)
Virological Failure
Unadjusted Analysis Multivariate Analysis
IRR (95% CI) P IRR (95% CI) P
Age at enrollment* 0.97 (0.95 to 0.99) 0.001 0.96 (0.94 to 0.98) ,0.001
Gender
Female 1
Male 0.80 (0.57 to 1.12) 0.186
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development of incident TB independently of immune func-
tion. Thus, poor virological control does not explain the high
TB incidence rates that persist during ART.10 In marked con-
trast, this study speciﬁcally demonstrated that risk of virolog-
ical failure was increased in the 6-month period after
a diagnosis of TB. There are several possible mechanisms
for this strong temporal association. TB and anti-TB treatment
may reduce adherence to ART because of high pill burden,
poor tolerability, adverse effects, or individuals being too
unwell to take ART. Impaired adherence may be exacerbated
by poorly integrated TB and HIV services, requiring patients to
obtain ART and TB medication from separate clinical
TABLE 2. (Continued ) Unadjusted and Multivariate Analyses of Risk Factors for Virological Breakthrough and Virological Failure
During ART
Virological Failure
Unadjusted Analysis Multivariate Analysis
IRR (95% CI) P IRR (95% CI) P
WHO stage at enrollment
1 and 2 1
3 1.33 (0.90 to 1.96) 0.084
4 0.90 (0.56 to 1.46)
Baseline CD4 cell count (cells/mL)
$150 1
100–149 1.33 (0.85 to 2.08)
50–99 1.32 (0.85 to 2.05) 0.336
,50 1.48 (0.96 to 2.29)
Baseline viral load (log10 copies/mL)
,5 1
$5 1.35 (0.99 to 1.84) 0.058
Duration of ART (mo)
,24 1 1
24–36 1.15 (0.80 to 1.65) 2.18 (1.49 to 3.20)
36–48 1.27 (0.88 to 1.83) 0.025 2.79 (1.86 to 4.18) ,0.001
48–60 0.69 (0.43 to 1.13) 1.73 (1.03 to 2.91)
.60 1.58 (1.05 to 2.36) 4.53 (2.83 to 7.25)
Updated CD4 cell count (cells/mL)†
.500 1 1
401–500 1.97 (1.01 to 3.84) 2.46 (1.26 to 4.80)
301–400 3.86 (2.18 to 6.82) 5.7 (3.19 to 10.23)
201–300 5.62 (3.25 to 9.72) ,0.001 9.95 (5.61 to 17.66) ,0.001
101–200 11.12 (6.51 to 19.01) 23.48 (13.05 to 42.23)
0–100 17.55 (9.34 to 32.96) 28.16 (14.21 to 55.84)
ART regimen†
Efavirenz based 1 1
Nevirapine based 1.34 (0.94 to 1.92) 1.51 (1.04 to 2.20)
PI based 1.62 (1.04 to 2.51) 0.089 1.15 (0.73 to 1.83) 0.194
Other — —
History of TB‡
No 1
Yes 0.83 (0.62 to 1.12) 0.231
Prevalent TB at baseline§
No 1 1
Yes 1.38 (1.00 to 2.19) 0.050 1.47 (1.07 to 2.00) 0.018
Incident TB†
No 1
Yes 1.57 (1.12 to 2.19) 0.010
No incident TB 1 1
6-mo period before TB diagnosis 2.05 (1.11 to 3.78) 0.020 1.31 (0.69 to 2.49)
6-mo period after TB diagnosis 4.19 (2.59 to 6.78) ,0.001 2.62 (1.60 to 4.29) 0.004
Time . 6 mo after TB diagnosis 1.24 (0.84 to 1.83) 0.021 0.96 (0.64 to 1.43)
All P values were calculated using the likelihood ratio test.
* Age is included as continuous variable, the IRR represents a 1-year increase in age.
† CD4 cell counts, ART regimen, and incident TB are time-updated variables.
‡ Includes all TB episodes where anti-TB treatment was completed before ART enrollment.
§ TB episodes where patients are taking anti-TB treatment at ART initiation.
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services.30,31 In addition, pharmacokinetic interactions between
rifampicin-based TB treatment and ART may also be a contrib-
utory mechanism.32–34 Systemic release of proinﬂammatory
cytokines in patients with active TB may serve to provide
stimulus to HIV-1 replication.35,36 Prevalent TB was also
found to have a weak association with virological failure dur-
ing the ﬁrst year of ART and may be attributable to similar
underlying mechanisms, although these ﬁndings may also be
because of chance.
In this study, PI-based ART regimens were associated
with increased risk of virological breakthrough and failure
before but not after adjustment for other risk factors. This is
most likely because of PI-based regimens being used as
second-line treatment, most commonly following virological
failure. However, there was some evidence of an independent
association between NVP-based ART regimens and poor
virological outcomes. This could be a direct association with
NVP; existing studies have shown NVP-based regimens to
have inferior virological outcomes compared with EFV- or
PI-based regimens, especially in the context of rifampicin-
based TB treatment, although a recent randomized trial found
no difference.37–41 Alternatively, the relationship could be
confounded by pregnancy (for which data were not available
and adjustment was not made) as NVP-based regimens were
mostly prescribed for women who were pregnant or at risk of
pregnancy. Pregnancy has been independently associated
with worse virological outcomes.41
The ﬁndings of this study have several implications for
ART programs. First, further research is needed to explore the
mechanisms underlying the association between incident TB
and poor virological outcomes and to identify appropriate
interventions. However, there is also an immediate need to
recognize that patients with TB during ART are at increased
risk of poor virological outcomes and should, therefore, be
prioritized for virological monitoring where possible and
increased adherence support. The adherence support system
used in this cohort has previously been shown to be
associated with successful virological suppression in approx-
imately two thirds of patients with virological breakthrough
as also reported in this analysis.17 During the period of this
study, HIV care and TB treatment were provided by separate
nonintegrated services, which compromises efﬁcient delivery
of care as described elsewhere.30,31 Delivery of care for pa-
tients with HIV-associated TB must be strengthened, colo-
cated, and integrated. Finally, adjunctive interventions are
needed to prevent incident TB during ART, including the
use of isoniazid preventive therapy and effective infection
control measures in health care facilities.5,42,43
Strengths of this study include the large sample size,
long median duration of follow-up, completeness of the
dataset, high frequency of CD4 and VL testing, availability
of time-updated ART regimen data, high proportion of
microbiologically conﬁrmed TB diagnoses, and the use of
multiple-event analysis techniques. Although the observa-
tional design of the study has inherent limitations, including
the inability to establish a direct causal relationship between
TB and virological breakthrough and failure, the routine
programmatic conditions may improve the generalizability of
FIGURE 3. Virological breakthrough
( ) and virological failure ( ) IRR
associated with person-time accrued
following a diagnosis of incident TB,
6-month period before TB, 6-month
period after TB diagnosis, and time
. 6 months after TB diagnosis,
compared with person-time with no
incident TB diagnosis.
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the ﬁndings. The lack of data on treatment adherence and
side-effects are a limitation as we were unable to explore
these as potential mechanisms. Although this study cannot
exclude VL. 1000 copies per milliliter being a risk factor for
incident TB, the strong temporal relationship and lack of
association between time preceding TB diagnosis and VL
breakthrough do not support this explanation. Although other
opportunistic infections not accounted for in this study may
also be implicated in virological failure, most opportunistic
infections are strongly related to CD4 cell count, which was
adjusted for. There may be other social and biological risk
factors for poor virological outcomes that were not possible to
quantify or adjust for in this study. Although the LTFU rate
(18.9% over a median follow-up of 5.2 years) was consider-
ably lower than that of other ART programs in sub-Saharan
Africa,44 some may have had unascertained TB. However,
patients LTFU from this cohort in fact do not have poor
prognostic characteristics45 and do not have higher TB inci-
dence rates before LTFU.10
In conclusion, this study shows an association between
TB occurring during ART and virological breakthrough and
virological failure, and this association is strongly time
dependent. Patients developing TB during ART may beneﬁt
from targeted VL monitoring, intensiﬁed treatment support,
and adherence interventions that may be best delivered
through integrated TB-HIV services. Further research into
the underlying mechanisms and potential solutions is needed.
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